Moncef Slaoui

Moncef is a member of the Board and the Corporate Executive Team at GlaxoSmithKline. He was given overall responsibility for GSK's Oncology Business in 2010 and for GSK Vaccines in 2011. Prior to that he was Chairman, Research & Development, a position he had held since June 2006.
In his previous position as Senior Vice President, Worldwide Business Development and External Alliances, he served on the R&D Executive Team and spearheaded recent changes in R&D to enhance drug discovery and accelerate product development. Before that, in GSK Vaccines, he engineered the development of a robust vaccines pipeline, including Rotarix, to prevent infantile gastroenteritis, and Cervarix, to prevent cervical cancer.
Following a career in academia, he has demonstrated since joining the company in 1988 that he can create a strategic vision and then vigorously pursue it to develop new products that profoundly enhance healthcare.
Moncef earned a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium, and completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston. He was Professor of Immunology at the University of Mons, Belgium. Moncef has authored more than 100 scientific papers and presentations. Moncef is a member of the PhRMA and the Biotechnology Industry Organization boards in the USA, and a member of the Advisory Committee to the Director of National Institutes of Health. He is also an adviser to the Qatar Foundation, and a member of the Qatar Biomedical Research Institute Scientific Advisory Committee. He was a member of the Board of the Agency for Science, Technology & Research (A*STAR) until January 2011. A citizen of Morocco, Belgium and the USA, he is fluent in English, French, and Arabic.